Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) Research & Development (2019 - 2025)

Historic Research & Development for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to $112.9 million.

  • BridgeBio Pharma's Research & Development fell 628.51% to $112.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $465.9 million, marking a year-over-year decrease of 798.89%. This contributed to the annual value of $506.5 million for FY2024, which is 1113.64% up from last year.
  • According to the latest figures from Q3 2025, BridgeBio Pharma's Research & Development is $112.9 million, which was down 628.51% from $111.2 million recorded in Q2 2025.
  • BridgeBio Pharma's 5-year Research & Development high stood at $141.0 million for Q1 2024, and its period low was $90.9 million during Q4 2022.
  • In the last 5 years, BridgeBio Pharma's Research & Development had a median value of $111.4 million in 2025 and averaged $113.1 million.
  • Its Research & Development has fluctuated over the past 5 years, first soared by 7963.94% in 2021, then plummeted by 2561.21% in 2022.
  • Over the past 5 years, BridgeBio Pharma's Research & Development (Quarter) stood at $122.2 million in 2021, then fell by 25.61% to $90.9 million in 2022, then skyrocketed by 43.26% to $130.2 million in 2023, then increased by 0.1% to $130.4 million in 2024, then dropped by 13.41% to $112.9 million in 2025.
  • Its Research & Development was $112.9 million in Q3 2025, compared to $111.2 million in Q2 2025 and $111.4 million in Q1 2025.